Associations of cardiovascular risk biomarkers with clinical status parameters in patients with comorbid hypertension

Aim. To evaluate the associations of cardiovascular risk biomarkers with clinical status parameters in patients with hypertension (HTN) depending on metabolic disorders.

Material and methods. We studied the associations of clinical status parameters, cardiovascular risk factors, and biomarkers in patients aged 25 to 74 years with HTN with and without metabolic disorders.

Results. Systolic blood pressure was positively associated with body mass index in both groups (p<0,05). In patients with HTN and metabolic disorders, concentric left ventricular hypertrophy was detected 2,3 times more often (p=0,001), while pseudonormal left ventricular diastolic dysfunction — 2 times more often (p=0,026), heart failure with reduced ejection fraction — 1,3 times more often (p=0,126). Higher values of combined hyperlipidemia were determined compared to patients with HTN without metabolic disorders. The concentration of N-terminal pro-brain natriuretic peptide was not associated with metabolic disorders (p=0,459), and was closely related to age (p=0,001).

Conclusion. In patients with hypertension, elevated systolic blood pressure is associated with excess body weight, regardless of metabolic disorders. Unfavorable indicators of clinical status and structural and geometric cardiac remodeling in patients with HTN and metabolic disorders are associated with abdominal and general obesity.

1. Shalnova SA, Yarovaya EB, Metelskaya VA, et al. The relationship of arterial hypertension, elevated low-density lipoprotein cholesterol and their combination with the occurrence of new cases of cardiovascular diseases in men and women of working age. Rational Pharmacotherapy in Cardiology. 2024;20(2):183-93. (In Russ.) doi:10.20996/1819-6446-2024-3013. EDN: IWKEIT.

2. Bilevich OA, Ovsyannikov NV, Usacheva EV, et al. Conventional and optional cardiovascular risk factors in predicting outcome in hemodialysis patients. Cardiovascular Therapy and Prevention. 2020;19(3):2304. (In Russ.) doi:10.15829/17288800-2020-2304.

3. Kukharchuk VV, Ezhov MV, Sergienko IV, et al. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations VII revision. Atherosclerosis and Dyslipidemia. 2020;(1):7-40. (In Russ.) DOI: 10.34687/2219-8202.JAD.2020.01.0002. EDN: ZFAWEI.

4. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. doi:10.1093/eurheartj/ehz455.

5. Kobalava ZhD, Konradi AO, Nedogoda SV, et al. 2024 Clinical practice guidelines for Hypertension in adults. Russian Journal of Cardiology. 2024;29(9):6117. (In Russ.) doi:10.15829/15604071-2024-6117.

6. Ostroumova OD, Cherniaeva MS. Arterial hypertension, cognitive disorders and dementia: a view of a cardiologist. S. S. Korsakov Journal of Neurology and Psychiatry. 2018;118(9):117-25. (In Russ.) doi:10.17116/jnevro2018118091117.

7. Shin D, Choi JM, Lee HY, et al. Suboptimal control status of young hypertensive population. Clinical Hypertension. 2023;29:13. doi:10.1186/s40885-023-00237-6.

8. Chumakova GA, Kuznetsova TYu, Druzhilov MA, et al. Visceral adiposity as a global factor of cardiovascular risk. Russian Journal of Cardiology. 2018;(5):7-14. (In Russ.) doi:10.15829/15604071-2018-5-7-14.

9. Chesnikova AI, Batyushin MM, Terentyev VP. Arterial hypertension and comorbidity: state of the art. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2016;22(5):432-40. (In Russ.) doi:10.18705/1607-419X-2016-22-5-432-440.

10. Koenen M, Hill MA, Cohen P, et al. Obesity, adipose tissue and vascular dysfunction. Circ Res. 2021;128(7):951-68. doi:10.1161/CIRCRESAHA.121.318093.

11. Brosolo G, Da Porto A, Marcante S, et al. Lipoprotein (a): Just an Innocent Bystander in Arterial Hypertension? Int J Mol Sci. 2023; 24(17):13363. doi:10.3390/ijms241713363.

12. Vedenskaya SS, Smolenskaya OG. Increased lipoprotein (a) as an additional factor in the failure to achieve target blood pressure levels and lipid spectrum optimal parameters in patients with arterial hypertension and multifocal atherosclerosis. Rational Pharmacotherapy in Cardiology. 2024;20(4):426-32. (In Russ.) doi:10.20996/1819-6446-2024-3081. EDN ZOMCRH.

13. Ulloque-Badaracco JR, Al-kassab-Córdova A, Hernandez-Bustamante EA, et al. Association of apolipoproteins and lipoprotein(a) with metabolic syndrome: a systematic review and meta-analysis. Lipids Health Dis. 2023;22(1):98. doi:10.1186/s12944-023-01860-w.

14. Mychka VB, Vertkin AL, Vardaev LI, et al. Experts’ consensus on the interdisciplinary approach towards the management, diagnostics, and treatment of patients with metabolic syndrome. Cardiovascular Therapy and Prevention. 2013;12(6):41-82. (In Russ.) EDN: RSYQYP.

15. Chaulin AM, Duplyakov DV. Increased natriuretic peptides not associated with heart failure. Russian Journal of Cardiology. 2020; 25(4S):4140. (In Russ.) doi:10.15829/1560-4071-2020-4140. EDN: FFBPWY.

16. Drapkina OM, Shepel RN, Dzhioeva ON. Natriuretic peptides: new challenges — new solutions. Cardiovascular Therapy and Prevention. 2021;20(7):3102. (In Russ.) doi:10.15829/1728-8800-2021-3102.

17. Wang HH, Lee DK, Liu M, et al. Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome. Pediatr Gastroenterol Hepatol Nutr. 2020;23(3):189-230. doi:10.5223/pghn.2020.23.3.189.

18. Dedov II, Shestakova MV, Melnichenko GA, et al. Interdisciplinary clinical practice guidelines "Management of obesity and its comorbidities". Obesity and Metabolism. 2021;18(1):5-99. (In Russ.) doi:10.14341/omet12714.

19. Kashirina AP, Simonova GI. Non-high-density lipoproteins cholesterol and cardiometabolic diseases. Ateroscleroz. 2024; 20(2):183-94. (In Russ.) doi:10.52727/2078-256X-2024-20-2-183-194.

20. Tsygankova OV, Bondareva KI, Latyntseva LD, et al. Clinical and pathophysiological role of lipoprotein (a) in the development of diseases associated with atherosclerosis. RMJ. 2020;28(12):4-8. (In Russ.). EDN: JHRWII.

21. Polyakova EA, Khalimov IS, Bazhenova EA, et al. Lipoprotein(a), atherosclerosis and cardiovascular risk. Rational Pharmacotherapy in Cardiology. 2024;20(5):559-65. (In Russ.). doi:10.20996/1819-6446-2024-3080.

22. Tsygankova DP, Krivoshapova KE, Maksimov SA, et al. Obesity and hypertension: the role of criteria. Systemic Hypertension. 2019;16(1):32-6. (In Russ.) doi:10.26442/2075082X.2019.180168.

23. Bodrova EA, Babaeva AR, Osadchuk MA, Solodenkova KS. Peculiarities of cardiac remodeling and myocardial dysfunction in metabolic syndrome. Diagnostic radiology and radiotherapy. 2020; 11(4):52-9. (In Russ.) doi:10.22328/2079-5343-2020-11-4-52-59.

24. Gorbachenkov AA, Borzova NV, Ananyeva SP, et al. Heart failure with predominant diastolic dysfunction. Russian Journal of Cardiology. 2006:11(S):44-52. (In Russ.) EDN: KZMWKP.

25. Tsygankova OV, Evdokimova NE, Latyntseva LD. Chronic heart failure with preserved ejection fraction amid prediabetes and abdominal obesity: fat depot compartments and cardiometabolic risk markers. Russian Medical Inquiry. 2023;7(1):22-9. (In Russ.) doi:10.32364/2587-6821-2023-7-1-22-29.